Redeye comments on Cellavision's first quarter 2025, which saw organic sales growth of 14%, an outstanding figure. Growth was mainly driven by instrument sales in EMEA. The outlook for the rest of the year is positive, with the caveat that an appreciating SEK will have a negative effect on the final growth rate.
LÄS MER